Boston Biotech Investor

The Boston Biotech Investor offers research reports on small cap biotechnology investments.

[Boston Biotech Investor @boston_biotech]

Is #UroGen still a great value?

https://t.co/dGwkIks8Lp

$URGN
#biotechinvesting
#biotech
#stockstobuy
#stockmarkettip
#investingtips

[Boston Biotech Investor @boston_biotech]

The subject video details the change in $BYSI market cap & enterprise value in November 2020.

https://t.co/3wX8vaRiR1

#beyondspring
#BYSI
#biotech
#stockstobuy
#stockalert
#investingtips
#biotechinvesting
#plinabulin

[Boston Biotech Investor @boston_biotech]

Our review of the $UROV acquisition (or remaining 27% not owned) by #Sumitovant at $16.25/share. We've always liked #urovant.

#UROV #biotech #NASDAQ #investing #investingtips #stockmarkets #stockresearch #marketresearch

https://t.co/klTZZZeGof

[Boston Biotech Investor @boston_biotech]

Our $BCLI analysis concludes shares fell 45% last month for no good reason (we could be wrong). Watch our video shared with our Pro members last Sunday.

https://t.co/Vyb8l5WFfG

#brainstormcell #stockstowatch #StockTrading #NASDAQ100 #biotechs #stockmarketnews

[Boston Biotech Investor @boston_biotech]

At $14.15/share, $KPTI trades at 5.9X consensus 2021 revenues. Really? Gilead paid 5X $IMMU peak sales.

https://t.co/Daib1REzrM

#KPTI #karyopharm #stockmarketnews #investingtips #investments #NASDAQ

[Boston Biotech Investor @boston_biotech]

#investors interested in Frequency Therapeutics $FREQ should read our FREQ research report & video presentation published yesterday noting, among other things, FREQ's capital structure, FX-322 Phase 1 analysis & peak sales estimates.

#biotech #freq #stockstowatch #stockstobuy

[Boston Biotech Investor @boston_biotech]

We recommend investors do their own due diligence, because #1) we do not recommend stocks and #2) our analysis may be wrong...but consider $OPTN

https://t.co/sLNrsbutzG

#stockstowatch #stockstobuy #StocksToTrade #StockMarketWatch #Biotechnology #biotech

[Boston Biotech Investor @boston_biotech]

We just published our Cellectar Biosciences $CLRB research report on our website for Pro members at:

https://t.co/17JWmIw3hH

#cellectar #stockstowatch #stockstobuy #Biotechnology #investors #NASDAQ

[Boston Biotech Investor @boston_biotech]

We would be thrilled if you would follow our YouTube Channel at:

https://t.co/oOMUs4IG61

Thank you.

#biotech #investing #investingtips #StockMarket #stockstowatch #StocksToTrade #stockstobuy #InvestmentManagers #Biotechnology #FolloMe

[Boston Biotech Investor @boston_biotech]

FY2020 share price performance of #biotech #stocks with their 1st or 2nd #FDA approval.

https://t.co/xSMAqrZbuY

$KALA $EVOK $EVFM $VYNE $ITCI $ZGNX $VIE $EPZM $EIGR $BCRX $SCPH #StockTrading #stocks #stocktips #biotech
#StockMarket #NASDAQ100

[Boston Biotech Investor @boston_biotech]

@jfais20 Thank you very much. What a kind thing to say.

[Jonathan Faison @jfais20]

$KALA video analysis by @boston_biotech is worth your time- be hard pressed to find someone who digs into and understands the numbers better than he does

https://t.co/4TwO2IfGMj

[Boston Biotech Investor @boston_biotech]

We like $KALA if #eysuvis is approved by the FDA this week. #PDUFA Oct. 30, 2020. Watch our video to learn more.

https://t.co/0vRJdMCRmV

#stockstowatch #investors #investing #investingtips #stocktrading #NASDAQ

[Boston Biotech Investor @boston_biotech]

$FREQ MC to EV at various PPS incl. FREQ's current $22/share. The attached calculation below does not consider Q3 2020 cash burn.

Read our #FREQ research report at:
https://t.co/2Y6uWyhIsm

#stocktips #stockmarkets #investors #NASDAQ

[Boston Biotech Investor @boston_biotech]

We've updated our Akero Therapeutics (AKRO) research report dated October 19, 2020 on our website at https://t.co/2Y6uWyhIsm

The following is only our overiew at:
https://t.co/F69Z2k1uGR

#stockstowatch #StockMarket #biotech

[Boston Biotech Investor @boston_biotech]

We've added four new small(er) cap #biotech company research reports including #ardelyx $ARDX, #Xeris $XERS, #optinose $OPTN & #KALA Pharma $KALA. 2 more imminent $UROV & $SCPH

#investingtips #SmallCaps

[Boston Biotech Investor @boston_biotech]

Our written research report & analysis on $SBBP is available for download (PDF) and video presentation for viewing at no cost at:

https://t.co/PBKFiPoAwA

We've thoroughly reviewed 25 other small(er) cap biotechs in the same manner. #investingtips

[Boston Biotech Investor @boston_biotech]

Overview of $BMY $MYOK #buyout. #biotech #investor #peaksales

https://t.co/zZHWZjlOGX

[Boston Biotech Investor @boston_biotech]

Our small cap biotech index Q3 2020 performance versus the larger cap biotech universe & quick reviews of $GTHX $CHMA $SBBP & $OPTN

https://t.co/gO8aMuGxXH